
There is enormous interest in the treatment of pulmonary zzso hypertension zzso so it is appropriate to consider the design of trials of new therapies and the zzso to be measured when trying to decide whether or not a therapy is zzso In May 2003, the first meeting devoted solely to the discussion of zzso and trial design in zzso was held in zzso zzso At that time, most of the zzso controlled trials in zzso had used zzso walking distance and/or resting zzso as their primary zzso The present article considers the progress that has been made since zzso It deals with aspects of clinical trial design (such as zzso superiority and withdrawal zzso considers zzso used in previous and current studies (such as zzso walking distance, time to clinical zzso zzso imaging and plasma brain zzso zzso and considers what zzso might be used in the zzso The second zzso meeting was held in zzso zzso in June zzso It had a similar format to the first zzso Much of what is presented here is a summary of the workshops from that zzso An attempt has been made to both zzso the current state of zzso and trial design and suggest new ways in which they could be zzso The present article forms one of a series being published in the European Respiratory Journal on pulmonary zzso 

